IXHL — Incannex Healthcare Share Price
0.000.00%
Last trade - 00:00- $121.14m
- $106.10m
- $0.09m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.05 | ||
| Price to Tang. Book | 9.05 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1,408.61 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -187.63% | ||
| Return on Equity | -381.09% | ||
| Operating Margin | -29373.26% | ||
Financial Summary
| Year End 30th Jun | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.47 | 0.57 | n/a | 0.01 | 0.09 | 0.69 | n/a | -31.02% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.
Directors
- Troy Valentine NEC
- Joel Latham CEO
- Mark Bleakley CFO
- Alistair Blake CTO
- Graham Howard GMG
- Sudhanshu Agarwal OTH
- Glenn Fowles SEC
- Peter Widdows NED
- Last Annual
- June 30th, 2025
- Last Interim
- June 30th, 2025
- Incorporated
- July 5th, 2023
- Public Since
- March 18th, 2022
- No. of Shareholders
- 4,657
- No. of Employees
- 12
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 347,705,507
- Address
- 8 Century Circuit, Ste. 105, Norwest, NEW YORK, 2153
- Web
- Phone
- Auditors
- Grant Thornton Audit Pty Ltd
Upcoming Events for IXHL
Incannex Healthcare Inc Annual Shareholders Meeting
Q2 2026 Incannex Healthcare Inc Earnings Release
Similar to IXHL
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the Incannex Healthcare share price?
As of Today at 21:17 UTC, shares in Incannex Healthcare are trading at $0.35. This share price information is delayed by 15 minutes.
How has the Incannex Healthcare share price performed this year?
Shares in Incannex Healthcare last closed at $0.35 and the price had moved by -83.25% over the past 365 days. In terms of relative price strength the Incannex Healthcare share price has underperformed the S&P500 Index by -85.26% over the past year.
What are the analyst and broker recommendations for Incannex Healthcare?
There is no consensus recommendation for this security.
Find out moreWhat is the Incannex Healthcare dividend yield?
Incannex Healthcare does not currently pay a dividend.
Does Incannex Healthcare pay a dividend?
Incannex Healthcare does not currently pay a dividend.
When does Incannex Healthcare next pay dividends?
Incannex Healthcare does not currently pay a dividend.
How do I buy Incannex Healthcare shares?
To buy shares in Incannex Healthcare you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Incannex Healthcare?
As of the previous close price of $0.35, shares in Incannex Healthcare had a market capitalisation of $121.14m.
Where are Incannex Healthcare shares listed?
Here are the trading details for Incannex Healthcare:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: IXHL
What kind of share is Incannex Healthcare?
Based on an overall assessment of its quality, value and momentum Incannex Healthcare is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Incannex Healthcare share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Incannex Healthcare share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Incannex Healthcare. Over the past six months, its share price has underperformed the S&P500 Index by -55.06%.
As of the last closing price of $0.35, shares in Incannex Healthcare were trading -53.34% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Incannex Healthcare PE Ratio?
The Incannex Healthcare PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Incannex Healthcare?
Incannex Healthcare's management team is headed by:
- Troy Valentine - NEC
- Joel Latham - CEO
- Mark Bleakley - CFO
- Alistair Blake - CTO
- Graham Howard - GMG
- Sudhanshu Agarwal - OTH
- Glenn Fowles - SEC
- Peter Widdows - NED